Enter your e-mail address below
to reset your password.
Please activate your registration
by clicking the link in the activation email
or click submit to resend the activation email.
Please check your spam folder too...
Check your mailbox to activate your registration.
Please check your spam folder too.
Hungarian drug maker Gedeon Richter on Thursday said it its Swiss unit PregLem signed an exclusive licensing agreement with Watson Laboratories to develop and market a drug to treat uterine fibroids in the United States and Canada.
Watson will pay PregLem a $17 million license fee along with royalties for the drug, called Esmya. Watson will make additional payments based on the achievement of regulatory milestones. (MTI-Econews)